Press release
Heart failure with Reduced Ejection Fraction Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, Stealth BioTherapeutics Inc
DelveInsight's "Heart failure with Reduced Ejection Fraction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Heart failure with Reduced Ejection Fraction, historical and forecasted epidemiology as well as the Heart failure with Reduced Ejection Fraction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Heart failure with Reduced Ejection Fraction market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Heart failure with Reduced Ejection Fraction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heart failure with Reduced Ejection Fraction Market Insights
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Heart failure with Reduced Ejection Fraction Market Report:
• The Heart failure with Reduced Ejection Fraction market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Heart failure with reduced ejection fraction (HFrEF) occurs when the Ejection Fraction is less than or equal to 40%
• In 2021, it was estimated that there were around 5 million diagnosed prevalent cases of heart failure in the United States. These numbers are projected to rise over the period under investigation from 2019 to 2032.
• In 2021, there were approximately 2 million estimated cases of Heart Failure with Reduced Ejection Fraction (HFrEF) in the United States.
• Heart Failure is a significant public health problem with a prevalence of over 5.8 to 6.5 million in the United States
• According to data from the Framingham Heart Study, the prevalence of heart failure rises with age, with 8 men per 1000 men aged 50 to 59 years and 66 men per 1000 men aged 80 to 89 years, and comparable numbers for women (8 and 79 per 1000)
• Key Heart failure with Reduced Ejection Fraction Companies: Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, Stealth BioTherapeutics Inc., PhaseBio Pharmaceuticals Inc., AstraZeneca, Sardocor Corp., Berlin Cures GmbH, Innolife Co., Ltd., Bayer, Zensun Sci. & Tech. Co., Ltd., Olatec Therapeutics LLC., Intra-Cellular Therapies, Inc., Asklepios Biopharmaceutical, Inc., and others
• Key Heart failure with Reduced Ejection Fraction Therapies: IONIS-AGT-LRx, Omecamtiv mecarbil, and others
Heart failure with Reduced Ejection Fraction Overview
Heart failure with reduced ejection fraction (HFrEF) is a type of heart failure characterized by the heart's inability to pump blood efficiently. In HFrEF, the left ventricle, the heart's main pumping chamber, becomes weakened and fails to contract effectively during each heartbeat. This results in a reduced ejection fraction, which refers to the percentage of blood pumped out of the left ventricle with each heartbeat.
Get a Free sample for the Heart failure with Reduced Ejection Fraction Market Report:
https://www.delveinsight.com/report-store/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Market
The dynamics of the Heart failure with Reduced Ejection Fraction market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Heart failure with Reduced Ejection Fraction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Heart failure with Reduced Ejection Fraction Epidemiology Segmentation:
The Heart failure with Reduced Ejection Fraction market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Heart failure with Reduced Ejection Fraction
• Prevalent Cases of Heart failure with Reduced Ejection Fraction by severity
• Gender-specific Prevalence of Heart failure with Reduced Ejection Fraction
• Diagnosed Cases of Episodic and Chronic Heart failure with Reduced Ejection Fraction
Download the report to understand which factors are driving Heart failure with Reduced Ejection Fraction epidemiology trends @ Heart failure with Reduced Ejection Fraction Epidemiological Insights
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Heart failure with Reduced Ejection Fraction market or expected to get launched during the study period. The analysis covers Heart failure with Reduced Ejection Fraction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Heart failure with Reduced Ejection Fraction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Heart failure with Reduced Ejection Fraction treatment, visit @ Heart failure with Reduced Ejection Fraction Medications
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Therapies and Key Companies
• IONIS-AGT-LRx: Ionis Pharmaceuticals
• Omecamtiv mecarbil: Cytokinetics
Scope of the Heart failure with Reduced Ejection Fraction Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Heart failure with Reduced Ejection Fraction Companies: Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, MYK-491, Stealth BioTherapeutics Inc., PhaseBio Pharmaceuticals Inc., AstraZeneca, Sardocor Corp., Berlin Cures GmbH, Innolife Co., Ltd., Bayer, Zensun Sci. & Tech. Co., Ltd., Olatec Therapeutics LLC., Intra-Cellular Therapies, Inc., Asklepios Biopharmaceutical, Inc., and others
• Key Heart failure with Reduced Ejection Fraction Therapies: IONIS-AGT-LRx, Omecamtiv mecarbil, and others
• Heart failure with Reduced Ejection Fraction Therapeutic Assessment: Heart failure with Reduced Ejection Fraction current marketed and Heart failure with Reduced Ejection Fraction emerging therapies
• Heart failure with Reduced Ejection Fraction Market Dynamics: Heart failure with Reduced Ejection Fraction market drivers and Heart failure with Reduced Ejection Fraction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Heart failure with Reduced Ejection Fraction Unmet Needs, KOL's views, Analyst's views, Heart failure with Reduced Ejection Fraction Market Access and Reimbursement
Discover more about therapies set to grab major Heart failure with Reduced Ejection Fraction market share @ Heart failure with Reduced Ejection Fraction market forecast
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Heart failure with Reduced Ejection Fraction Market Report Introduction
2. Executive Summary for Heart failure with Reduced Ejection Fraction
3. SWOT analysis of Heart failure with Reduced Ejection Fraction
4. Heart failure with Reduced Ejection Fraction Patient Share (%) Overview at a Glance
5. Heart failure with Reduced Ejection Fraction Market Overview at a Glance
6. Heart failure with Reduced Ejection Fraction Disease Background and Overview
7. Heart failure with Reduced Ejection Fraction Epidemiology and Patient Population
8. Country-Specific Patient Population of Heart failure with Reduced Ejection Fraction
9. Heart failure with Reduced Ejection Fraction Current Treatment and Medical Practices
10. Heart failure with Reduced Ejection Fraction Unmet Needs
11. Heart failure with Reduced Ejection Fraction Emerging Therapies
12. Heart failure with Reduced Ejection Fraction Market Outlook
13. Country-Wise Heart failure with Reduced Ejection Fraction Market Analysis (2019-2032)
14. Heart failure with Reduced Ejection Fraction Market Access and Reimbursement of Therapies
15. Heart failure with Reduced Ejection Fraction Market Drivers
16. Heart failure with Reduced Ejection Fraction Market Barriers
17. Heart failure with Reduced Ejection Fraction Appendix
18. Heart failure with Reduced Ejection Fraction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heart failure with Reduced Ejection Fraction Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, Stealth BioTherapeutics Inc here
News-ID: 3459189 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
